Accessible Search Form           Advanced Search

Skip left side navigation and go to content


Lung Vascular Research

Executive Summary

The Division of Lung Diseases of the National Heart Lung Blood Institute (NHLBI), with the Office of Rare Diseases Research (ORDR), held a workshop on march 8-9, 2010 to identify priority areas and strategic goals to enhance and accelerate research that will result in improved understanding of the lung vasculature, translational research needs, and ultimately the care of patients with pulmonary vascular diseases. Multi-disciplinary experts with diverse experience in laboratory, translational and clinical studies identified seven priority areas and discussed limitations in our current knowledge, technologies and approaches. The focus for future research efforts include: a) better characterizing vascular genotype-phenotype relationships and incorporating systems approaches when appropriate; b) advancing our understanding of pulmonary vascular metabolic regulatory signaling in health and disease; c) expanding our knowledge of the biologic relationships between the lung circulation and circulating elements, systemic vascular function, and right heart function and disease; d) improving translational research for identifying disease-modifying therapies for the pulmonary hypertensive diseases; e) establishing an appropriate and effective platform for advancing translational findings into clinical studies testing, and f) developing the specific technologies and tools that will be enabling for these goals, such as question-guided imaging techniques and lung vascular investigator training programs. Recommendations from this Workshop will be utilized within the Lung Vascular Biology and Disease Extramural Research Program for planning and strategic implementation purposes


  1. Advance basic scientific research in lung vascular biology utilizing emerging technologies.
  2. Advance and coordinate basic and clinical knowledge of the pulmonary circulation-right heart axis through novel research efforts utilizing multidisciplinary teams.
  3. Define interactions between lung vascular components and circulating elements and systemic circulations by fostering novel collaborations.
  4. Encourage systems analysis to understand and define interactions between lung vascular genetics, epigenetics, metabolic pathways, and molecular signaling.
  5. Develop strategies using appropriate animal models to improve the understanding of the lung vasculature in health and in conditions that reflect human disease.
  6. Enhance translational research in lung vascular disease by comparing cellular and tissue abnormalities identified in animal models to those in human specimens.
  7. Improve lung vascular disease molecular and clinical phenotype coupling.
  8. Develop in vivo imaging techniques which assess structural changes in lung vasculature, metabolic shifts, functional cell responses and right ventricular function.
  9. Develop research consortia that advance basic, translational, and clinical studies, allow for multi-center epidemiological study feasibility, and support junior investigators’ training in lung vascular biology and disease.

Working Group Members


  • Serpil Erzurum, M.D., Cleveland Clinic, Cleveland, OH
  • Sharon Rpimds, M.D., Providence VA Medical Center; Provicence, RI
  • Troy Stevens, Ph.D., University of Alabama; Mobile, AL


  • Micheala Aldred, Ph.D., Cleveland Clinic
  • Jason Aliotta, M.D., Brown University
  • Stephen Archer, M.D., University of Chicago
  • Kewal Asosingh, Ph.D., Cleveland Clinic
  • Robert Balaban, M.D., Columbia University
  • Natalie Bauer, Ph.D., University of South Alabama
  • Jahar Bhattacharya, M.D., Columbia University
  • Herman Bogaard, M.D., Virginia Commonwealth University
  • Gaurav Choudhary, M.D., Brown University
  • Gerald W. Dorn II, M.D., Washington University
  • Raed Dweik, M.D., Cleveland Clinic
  • Karen Fagan, M.D., University of South Alabama
  • Michael Fallon, M.D., University of Texas-Houston
  • Mark Geraci, M.D., University of Colorado-Denver
  • Mark T. Gladwin, M.D., University of Pittsburgh
  • Paul M. Hassoun, M.D., Johns Hopkins University
  • Marc Humbert, M.D., Ph.D., Université Paris-Sud 11
  • Naftali Kaminski, M.D., University of Pittsburgh
  • Steven K. Kawut, M.D., University of Pennsylvania
  • Joseph Loscalzo, M.D., Ph.D., Brigham and Women’s Hospital
  • Donald McDonald, M.D., University of California-San Francisco
  • Ivan F. McMurtry, M.D., University of South Alabama
  • John Newman, M.D., Vanderbilt University
  • Mark Nicolls, M.D., Palo Alto Institute
  • Marlene Rabinovitch, M.D., Stanford University
  • Judy Shizuru, M.D., Stanford University
  • Masahiko Oka, M.D., University of South Alabama
  • Peter Polgar, M.D., Boston University
  • David Rodman, M.D., Novartis Institutes for Biomedical Research
  • Paul Schumacker, Ph.D., Northwestern University
  • Kurt Stenmark, M.D., University of Colorado-Denver
  • Rubin Tuder, M.D., University of Colorado-Denver
  • Norbert Voelkel, M.D., Virginia Commonwealth University
  • Eugene Sullivan, M.D., United Therapeutics
  • Richard Weinshilboum, M.D., Mayo Medical School-Mayo Clinic
  • Mervin C. Yoder, M.D., Indiana University
  • Yingming Zhao, Ph.D., University of Chicago


  • Dorothy Gail, M.D., Division of Lung Diseases
  • Timothy Moore, Ph.D., Division of Lung Diseases
  • Toren Finkel, M.D., Ph.D. Translational Medicine.

Office of Rare Diseases

  • Stephen C. Croft, Pharm. D.

Last Updated: January 2011

Twitter iconTwitterimage of external icon Facebook iconFacebookimage of external icon YouTube iconYouTubeimage of external icon Google+ iconGoogle+image of external icon